Third, Vertex still has an exciting pipeline in CF and elsewhere. For instance, the company's late-stage candidate for APOL-1 ...

Wall Street analysts forecast that Vertex Pharmaceuticals (VRTX) will report quarterly earnings of $4.24 per share in its upcoming release, pointing to a year-over-year increase of 133.1%. It is ...

Vertex Pharmaceuticals trades at $469.50 and has moved in lockstep with the market. Its shares have returned 6.5% over the ...

This was the stock's third consecutive day of losses.

Few things can jolt a pharmaceutical company's shares like positive results from highly anticipated clinical trials. Even so, ...

We recently compiled a list of 10 Most Undervalued Healthcare Stocks to Buy According to Analysts. Vertex Pharmaceuticals ...

U.S. equities rebounded strongly in Q2, with growth stocks and mid-caps leading gains; our portfolio outperformed via IT, ...

Vertex Pharmaceuticals Inc. closed 10.71% below its 52-week high of $519.88, which the company reached on November 8th.

Over the past decade, Vertex Pharmaceuticals (NASDAQ: VRTX) has delivered above-average returns. The secret behind the biotech's success isn't much of a secret. The drugmaker developed and ...

Vertex Pharmaceuticals Share Price Analysis Shares of Vertex Pharmaceuticals were trading at $498.86 as of May 01. Over the last 52-week period, shares are up 24.51%.

Vertex Pharmaceuticals has solid revenue projections for its CF franchise, and a promising drug pipeline, especially in pain. Click to read why VRTX is a Buy.